ERBB2 and gastric cancer: Trastuzumab, the first monoclonal antibody against the HER2 receptor, was approved for clinical use, in combination with chemotherapy, as first-line treatment in patients with HER2-positive unresectable or metastatic gastric cancer in 2010 [50], representing a paradigm shift in the management of HER2-positive gastric cancer disease.